AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11564001 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg)
Number of subjects: 50
Study 11564001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9744013 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 33% solution
Number of subjects: 65
Study 9744013 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 5% solution
Number of subjects: 65
Study 9744013 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 65
Study 9744013 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 65
Study 8113846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment: cisplatin 100 mg/m2 over 15 minutes on day 1 plus 5‐FU 1.0 g/m2 by continuous infusion on days 1 to 5, followed by 70 Gy of radiation in 7 to 8 weeks.
Number of subjects: 214
Study 8113846 — intervention group
Group type: COMPARATOR
Intervention: Concomitant treatment: cisplatin 60 mg/m2 over 15 minutes on day 1 plus 5‐FU 800 mg/m2 by continuous infusion on days 1 to 5 plus radiation 2 Gy on days 1 to 5, repeated every other week for seven cycles.
Number of subjects: 214
Study 8113846 — intervention group
Group type: COMPARATOR
Intervention: Concomitant treatment
Number of subjects: 214
Study 8113846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment
Number of subjects: 214
Study 8113846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment and Concomitant treatment
Number of subjects: 214
Study 2962483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis
Number of subjects: 266
Study 2962483 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 266
Study 28918669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app for patient education and engagement
Number of subjects: 205
Study 28918669 — intervention group
Group type: COMPARATOR
Intervention: Spiral notebook guide for patient education and engagement
Number of subjects: 205
Study 26059709 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 120
Study 26059709 — intervention group
Group type: COMPARATOR
Intervention: 0·9% sodium chloride sterile solution
Number of subjects: 120
Study 25680887 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB) group: losartan 50 mg plus amlodipine 5 mg
Number of subjects: 109
Study 25680887 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACEI) group: enalapril 5 mg
Number of subjects: 109
Study 25680887 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretic (HCTZ) group: hydrochlorothiazide 12.5 mg
Number of subjects: 109
Study 25680887 — intervention group
Group type: COMPARATOR
Intervention: Control period (usual dose of ARB)
Number of subjects: 109
Study 23966328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk (475 mL)
Number of subjects: 19
Study 23966328 — intervention group
Group type: COMPARATOR
Intervention: Rice milk (isocaloric volume)
Number of subjects: 19
Study 21910712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 nm laser treatment (Candela Smoothbeam laser); 3 treatments performed monthly, using a double-pass technique, 6 mm spot size, 210 ms pulse duration, fluence of 8 or 9 J cm(‐2)
Number of subjects: 38
Study 21910712 — intervention group
Group type: COMPARATOR
Intervention: Control side (untreated side of the face)
Number of subjects: 38
Study 21910712 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 nm laser treatment
Number of subjects: 38
Study 18939389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering (hemoglobin A1c target < 6.0%)
Number of subjects: 10000
Study 18939389 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (hemoglobin A1c target 7.0% to 7.9%)
Number of subjects: 10000
Study 17023867 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (MPH-IR) at 2.5 mg t.i.d.
Number of subjects: 303
Study 17023867 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (MPH-IR) at 5 mg t.i.d.
Number of subjects: 303
Study 17023867 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (MPH-IR) at 7.5 mg t.i.d.
Number of subjects: 303
Study 17023867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 17023867 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-dose MPH
Number of subjects: 303
Study 12055318 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) diet
Number of subjects: 65
Study 12055318 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein (LP) diet
Number of subjects: 65
Study 12055318 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 10079408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) (n = 126 oocytes)
Number of subjects: 20
Study 10079408 — intervention group
Group type: COMPARATOR
Intervention: Standard insemination techniques (group II) (n = 138 oocytes)
Number of subjects: 20
Study 8838389 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice on a lateralized mental rotation task
Number of subjects: 92
Study 2359578 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored uterine activity
Number of subjects: 51
Study 2359578 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms
Number of subjects: 51
Study 2359578 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine activity
Number of subjects: 51
Study 2359578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical examination at a routine office visit
Number of subjects: 51
Study 7307036 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole tampons (2 tampons daily for 5 days)
Number of subjects: 51
Study 7307036 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole vaginal tablets (1 tablet daily for 6 days)
Number of subjects: 51
Study 30902692 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal keratitis treatment
Number of subjects: 100
Study 30902692 — intervention group
Group type: COMPARATOR
Intervention: Bacterial keratitis treatment
Number of subjects: 100
Study 28351060 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal
Number of subjects: 183
Study 26418530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) for 30 days
Number of subjects: 2876
Study 26418530 — intervention group
Group type: COMPARATOR
Intervention: No IPC (routine care)
Number of subjects: 2876
Study 26418530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 2876
Study 22407182 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTB graft
Number of subjects: 114
Study 22407182 — intervention group
Group type: EXPERIMENTAL
Intervention: DLSG graft
Number of subjects: 114
Study 21242676 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free hemodiafiltration (AF HFR)
Number of subjects: 30
Study 21242676 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate hemodiafiltration (HFR with acetate)
Number of subjects: 30
Study 21242676 — intervention group
Group type: COMPARATOR
Intervention: Standard bicarbonate dialysis (BHD)
Number of subjects: 30
Study 18945306 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA + IFN-alpha
Number of subjects: 29
Study 18945306 — intervention group
Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 29
Study 17669915 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 0
Study 15182379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by community pharmacists after training
Number of subjects: 700
Study 15182379 — intervention group
Group type: COMPARATOR
Intervention: Usual dispensing services provided by community pharmacists before training
Number of subjects: 700
Study 11510929 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 20
Study 11510929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9400878 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation-liaison psychiatry service (C-L) referrals without symptom-matched controls (n = 27)
Number of subjects: 86
Study 9400878 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-matched C-L referrals
Number of subjects: 86
Study 9400878 — intervention group
Group type: COMPARATOR
Intervention: Non-referred controls (matched on demographic characteristics)
Number of subjects: 86
Study 9400878 — intervention group
Group type: COMPARATOR
Intervention: Non-referred controls (matched on initial symptomatology)
Number of subjects: 86
Study 8287317 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoas training (TG)
Number of subjects: 78
Study 8287317 — intervention group
Group type: COMPARATOR
Intervention: Deltoid training (CG)
Number of subjects: 78
Study 3815287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 12
Study 3815287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31307209 — intervention group
Group type: EXPERIMENTAL
Intervention: Aligners (AL)
Number of subjects: 100
Study 31307209 — intervention group
Group type: COMPARATOR
Intervention: Fixed Appliances (FA)
Number of subjects: 100
Study 31549959 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked retrograde nail fixation
Number of subjects: 23
Study 31549959 — intervention group
Group type: COMPARATOR
Intervention: Anatomical distal femoral locking plate fixation
Number of subjects: 23
Study 28928192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (GTN)
Number of subjects: 0
Study 28928192 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (placebo)
Number of subjects: 0
Study 25079365 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra)
Number of subjects: 182
Study 25079365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 22777396 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional demands (unmet care needs)
Number of subjects: 1599
Study 22777396 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional demands (client health and emotional suppression)
Number of subjects: 1599
Study 22777396 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional demands (unfair treatment, client's family abuse)
Number of subjects: 1599
Study 21710402 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine (0.4 mg/kg)
Number of subjects: 24
Study 21710402 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 21710402 — intervention group
Group type: COMPARATOR
Intervention: social stress test (SST)
Number of subjects: 24
Study 19401341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICDs
Number of subjects: 334
Study 19401341 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber ICDs
Number of subjects: 334
Study 16846398 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide combination tablets (Glucovance)
Number of subjects: 50
Study 16846398 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 50
Study 16846398 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 50
Study 15144688 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 77
Study 15144688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 10702428 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma sequestration (pheresis)
Number of subjects: 55
Study 10702428 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 9402455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy intracardiac cardioversion (1 to 15 J)
Number of subjects: 187
Study 9402455 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic external cardioversion (360 J)
Number of subjects: 187
Study 8401150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion at 18 degrees, 22 degrees, or 26 degrees C for 120 min.
Number of subjects: 21
Study 3005138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin (12 g/day)
Number of subjects: 30
Study 3005138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose (15 g/day)
Number of subjects: 30
Study 3005138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignin (12 g/day)
Number of subjects: 30
Study 2851443 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP/MEC chemotherapy (cyclophosphamide 500 mg/m2 i.v. day 1; epirubicin 50 mg/m2 i.v. day 1; cisplatin 80 mg/m2 i.v. day 1; alternated with methotrexate 30 mg/m2 i.v. day 1; etoposide 200 mg/m2 i.v. day 1; CCNU 70 mg/m2 per os, day 1) until progression.
Number of subjects: 92
Study 2851443 — intervention group
Group type: COMPARATOR
Intervention: Supportive care (Arm B).
Number of subjects: 92
Study 31221047 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated symptom management (ASM)
Number of subjects: 0
Study 31221047 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive symptom management (CSM)
Number of subjects: 0
Study 30921804 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with house dust mite extract
Number of subjects: 6
Study 30921804 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-allergic individuals)
Number of subjects: 6
Study 28673214 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP catheter (18 ml 0.5% ropivacaine every four hours)
Number of subjects: 94
Study 28673214 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS catheter (18 ml 0.5% ropivacaine every four hours)
Number of subjects: 94
Study 28673214 — intervention group
Group type: EXPERIMENTAL
Intervention: SC catheter (18 ml 0.5% ropivacaine every four hours)
Number of subjects: 94
Study 25945018 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole plus irsogladine maleate (IM)
Number of subjects: 100
Study 25945018 — intervention group
Group type: COMPARATOR
Intervention: rabeprazole plus placebo
Number of subjects: 100
Study 25945018 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole plus irsogladine maleate (IM) in patients with NERD grade N
Number of subjects: 100
Study 23725944 — intervention group
Group type: EXPERIMENTAL
Intervention: BT + MT
Number of subjects: 64
Study 23725944 — intervention group
Group type: EXPERIMENTAL
Intervention: BT + VRS
Number of subjects: 64
Study 23725944 — intervention group
Group type: COMPARATOR
Intervention: box-free
Number of subjects: 64
Study 23725944 — intervention group
Group type: COMPARATOR
Intervention: BT
Number of subjects: 64
Study 21255767 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐week web‐based unguided self‐help treatment for social phobia
Number of subjects: 81
Study 21255767 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐week web‐based self‐help treatment with minimal weekly therapist support via email
Number of subjects: 81
Study 21255767 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐week web‐based self‐help treatment with flexibly stepped-up support (email or telephone contact on demand)
Number of subjects: 81
Study 21255767 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 81
Study 19298412 — intervention group
Group type: EXPERIMENTAL
Intervention: prulifloxacin 600 mg
Number of subjects: 72
Study 19298412 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 72
Study 16504691 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (PT) - tailored exercises under physiotherapist supervision for 15 to 30 minutes every second hospital day
Number of subjects: 69
Study 16504691 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CT) - control group
Number of subjects: 69
Study 12765806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (2,500 units once a day, SC, for 7 days)
Number of subjects: 100
Study 12765806 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000 units every 12 hours, SC, for 7 days)
Number of subjects: 100
Study 12765806 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 100
Study 12765806 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 100
Study 10983362 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (12.5-25 mg/daily)
Number of subjects: 60
Study 10983362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-20 mg/daily)
Number of subjects: 60
Study 10983362 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (10-25 mg/daily)
Number of subjects: 60
Study 10983362 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 60
Study 10983362 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 60
Study 10983362 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 60
Study 9313603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 310
Study 9313603 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 310
Study 9313603 — intervention group
Group type: COMPARATOR
Intervention: Mibefradil 6.25 mg, 12.5 mg, 25 mg, 50 mg, 100 mg
Number of subjects: 310
Study 9313603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 8383396 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment based on ambulatory monitoring
Number of subjects: 0
Study 8383396 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment based on conventional sphygmomanometry
Number of subjects: 0
Study 3536151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3796
Study 3536151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3796
Study 3536151 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine vs Placebo
Number of subjects: 3796
Study 28804889 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposcope-assisted double-lumen tube placement
Number of subjects: 54
Study 28804889 — intervention group
Group type: COMPARATOR
Intervention: Conventional blind placement
Number of subjects: 54
Study 25714534 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine 0.5% drops (Group Drops)
Number of subjects: 92
Study 25714534 — intervention group
Group type: EXPERIMENTAL
Intervention: Proparacaine 0.5% drops plus subconjunctival lidocaine (Group SC)
Number of subjects: 92
Study 25714534 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel (Group Gel)
Number of subjects: 92
Study 25169158 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes about school drinking fountains (measured on a 5-point scale)
Number of subjects: 3211
Study 25169158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentions to drink water at school
Number of subjects: 3211
Study 22645171 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus salivarius, 2 × 10^10 bacterium colony-forming units)
Number of subjects: 66
Study 22645171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 19086814 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision (MC)
Number of subjects: 1264
Study 19086814 — intervention group
Group type: COMPARATOR
Intervention: Control (uncircumcised)
Number of subjects: 1264
Study 17339157 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mL autologous blood
Number of subjects: 33
Study 17339157 — intervention group
Group type: COMPARATOR
Intervention: 15 mL autologous blood
Number of subjects: 33
Study 14998957 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate challenge test (CCCT)
Number of subjects: 85
Study 14998957 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal FSH (bFSH)
Number of subjects: 85
Study 14998957 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous FSH ovarian reserve test (EFORT)
Number of subjects: 85
Study 12018735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus vinorelbine
Number of subjects: 222
Study 12018735 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus paclitaxel
Number of subjects: 222
Study 9854760 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management group intervention
Number of subjects: 255
Study 9854760 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 255
Study 7503087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 57
Study 7503087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2089087 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg/d)
Number of subjects: 0
Study 2089087 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (100-200 mg/d)
Number of subjects: 0
Study 314760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (2 microgram/kg . min and 4 microgram/kg . min)
Number of subjects: 17
Study 314760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (4 microgram/kg . min and 8 microgram/kg . min)
Number of subjects: 17
Study 314760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both catecholamines
Number of subjects: 17
Study 314760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 17
Study 30117365 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (20 g/day)
Number of subjects: 11
Study 30117365 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (2,700 mg/day)
Number of subjects: 11
Study 30117365 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 11
Study 25138127 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-B2 group
Number of subjects: 180
Study 25138127 — intervention group
Group type: EXPERIMENTAL
Intervention: SP6 group
Number of subjects: 180
Study 25138127 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 25669080 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath laryngoscope
Number of subjects: 50
Study 25669080 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 50
Study 21450647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPX) in AAA patients
Number of subjects: 306
Study 21450647 — intervention group
Group type: COMPARATOR
Intervention: Referral group (age-matched veterans)
Number of subjects: 306